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Abstract
In the past few years a growing interest in vitamin D can be observed in the lay and biomedical literature due to
findings demonstrating a low vitamin D status in the population. In addition to its importance for the regulation of
calcium and phosphorus homeostasis recent epidemiologic studies have observed relationships between low
vitamin D levels and multiple disease states. This secosteroid hormone also regulates the expression of a large
number of genes in reproductive tissues implicating a role for vitamin D in female reproduction. In this report we
summarize the recent evidence that vitamin D status influences female reproductive and pregnancy outcomes.
Human and animal data suggest that low vitamin D status is associated with impaired fertility, endometriosis and
polycystic ovary syndrome. Evidence from observational studies shows higher rates of preeclampsia, preterm birth,
bacterial vaginosis and gestational diabetes in women with low vitamin D levels. However, confirmation of
experimental observations establishing an association of vitamin D deficiency with adverse reproductive outcomes
by high quality observational and large-scale randomized clinical trials is still lacking. The determination of optimal
25(OH)D3 levels in the reproductive period and the amount of vitamin D supplementation required to achieve
those levels for the numerous actions of vitamin D throughout a woman’s life would have important public health
implications.
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Background
In North America and Western Europe only small
amounts of vitamin D, a fat-soluble secosteroid hor-
mone, enter the metabolic circle via dietary uptake (e.g.
from fish), although dietary supplement intake has
increased in recent years (Figure 1). The main source
(about 95%) is vitamin D3 (cholecalciferol) that is photo-
chemically synthesized in the skin by ultraviolet-B radia-
tion. Thermal conversion of pro-vitamin D3 (7-
dehydrocholesterol) leads to pre-vitamin D3, which iso-
merizes into cholecalciferol. Cholecalciferol is bound to
serum vitamin D-binding protein (DBP) and through a
two-step enzymatic pathway involving 25-hydroxylase of
the liver and 1a-hydroxylase (CYP27B1) of the kidney
and extrarenal tissues, it is converted to the biologically
active hormone calcitriol (1a,25(OH)2D3) [1]. In a wide
variety of cell types vitamin D exerts its effects by bind-
ing to the vitamin D receptor (VDR), a member of the
nuclear steroid receptor superfamily and an intracellular
transcription factor [2]. The regulation of VDR expres-
sion is one of the main mechanisms through which tar-
get cells respond to calcitriol so that polymorphisms of
this receptor can change the usual mode of functioning.
Although 1,25(OH)2D3 is the biologically active form
of vitamin D the vitamin D status is mainly assessed by
the measurement of serum 25(OH)D3 concentration.
The test is used due to associations between vitamin D,
calcium and plasma parathyroid hormone (PTH) [3,4].
While becoming vitamin D deficient the parathyroid
glands increase the secretion of PTH to accelerate renal
calcium reabsorption and calcium release from bone.
Another effect of PTH is the stimulation of renal 1,25
(OH)2D3 production with possibly misleading 1,25(OH)
2D3 concentrations within the normal range.
Based on associations between plasma 25(OH)D3 and
PTH concentration, calcium absorption, bone turnover
markers, and bone mineral density, investigators have
argued that a plasma 25(OH)D3 concentration of greater
than 75 nmol/l (to convert to ng/ml divide by 2.5) is
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appropriate to define vitamin D sufficiency [5-7]. Pre-
cisely defining vitamin D deficiency or insufficiency is
still a matter of great debate. A rather simplistic scheme
for the classification of vitamin D status is shown in Fig-
ure 2. Although there is currently no consensus for opti-
mal levels, most experts use a plasma concentration of 25
(OH)D3 of 25 nmol/l as a conventional cut-off for defin-
ing the lower limit of adequacy of vitamin D status [8].
These cutoffs were derived from populations of non-
pregnant individuals. However, recent evidence
demonstrates that the prevalence of vitamin D deficiency
in women of childbearing age is surprisingly high [9-12].
Vitamin D plays a pivotal role in bone metabolism
and mineral homeostasis. Emerging data identify critical
roles for the active form of vitamin D (1a,25(OH)2D3)
in a variety of other biological processes including regu-
lation of cellular growth, differentiation and metabolic
modulations [13,14]. Beneficial roles for vitamin D in a
spectrum of pathologic processes, including autoimmu-
nity, insulin resistance, cardiovascular disease, and
Figure 1 Types and functions of vitamin D.
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malignancies, are emerging concomitantly with the
appreciation of a global pandemic of vitamin D defi-
ciency (Figure 3) [5,13,14]. Over the past decade the
physiological role of 1a,25(OH)2D3 has been investi-
gated extensively [15], but data regarding its role in
human reproduction are scarce [16-18]. Since the VDR
and 1a-hydroxylase are expressed in reproductive tis-
sues including ovary, uterus, placenta, testis and hypo-
physis an association with vitamin D and many potential
pathways linking vitamin D to reproductive health out-
comes almost suggests itself [19-21].
The aims of this review are to critically summarize the
most recent data regarding the association of vitamin D
deficiency and female reproductive outcomes. We
searched the PubMed and MEDLINE up to August 20
2011 using combinations of the following keywords:
vitamin D deficiency/insufficiency and pregnancy, repro-
duction, fertility/infertility, polycystic ovary syndrome,
endometriosis, preeclampsia, gestational diabetes, pre-
term birth and bacterial vaginosis. Randomized con-
trolled trials, original papers and review articles are
included in the present article.
Health implications of vitamin D deficiency in female
reproduction
Vitamin D and fertility
A seasonal distribution in human natural conception
and birth rates has been consistently demonstrated,
showing a peak conception rate during summer in
northern countries with strong seasonal contrast in
luminosity [22]. Experimental studies have demonstrated
that the ovary is a target organ for 1,25(OH)2D3 raising
the possibility that this active metabolite of vitamin D3
might play a role in modulating ovarian activity [23].
Experiments investigating the significance for fertility
and reproductive capacity, demonstrate that 25(OH)D3-
deficient female rats had reduced fertility rates,
decreased litter sizes and compromised mating behavior
[24]. VDR-null mice showed hypergonadotropic hypogo-
nadism with decreased aromatase activities in the ovary,
testis and epididymis, uterine hypoplasia, impaired folli-
culogenesis; decreased sperm counts, decreased sperm
motility and histological abnormalities of the testis [19].
Ablation of 1a-hydroxylase in female mice is accompa-
nied by abnormal ovarian follicle development, uterine
hypoplasia and infertility similar to VDR knockout mice
[25,26]. However, when serum calcium and phosphorus
were normalized by a rescue diet in the female 1a-
hydroxylase -/- mice, the defective phenotype including
dysfunction in the hypothalamic-pituitary-ovarian axis
and ovarian angiogenesis were reversed. The authors
conclude that the infertility seen in 1,25(OH)2D3-defi-
cient mice is an indirect effect mediated by extracellular
calcium and phosphorus and not a direct effect of vita-
min D deficiency [27,28]. Specific human data in this
context is sparse. The first study looking at vitamin D
and in vitro-fertilization (IVF) success in 10 healthy
women undergoing IVF and embryo transfer found an
association of raised oestradiol levels during gonadotro-
phin-induced ovarian stimulation and a significant
increase of serum 1,25(OH)2D3. (r = 0.787, p < 0.001)
[29,30]. Ozkan et al. recently showed higher pregnancy
Figure 2 Classification of vitamin D status and recommendations for substitution.
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and implantation rates across tertiles of 25(OH)D3 in
follicular fluid of 84 infertile women undergoing IVF
and proposed follicular fluid 25(OH)D3 levels as an
independent predictor to success of an IVF-cycle [31]
whereas two prospective studies with 101 and 82
women could not confirm these findings [32,33]. On the
contrary no significant differences in pregnancy rates
and embryo quality were found between patients with
low (< 50 nmol/l) and moderate (50-75 nmol/) 25(OH)
D3 follicular fluid levels, at high vitamin D levels in folli-
cular fluid (> 75 nmol/l) even a decrease in pregnancy
rate and embryo quality was seen [32,33]. It was also
shown that increased follicular fluid 25(OH)D3 levels in
combination with decreased follicular fluid glucose
levels have a negative impact on embryo quality and
therefore on IVF outcome [33]. Moreover, Estes and
colleagues found a decreased expression of DBP in the
follicular fluid of the IVF success group [34]. While the
results of human studies are contradictory the role of
vitamin D on human fertility and reproductive physiol-
ogy merits further assessment by appropriate longitudi-
nal studies.
Vitamin D and polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is among the most
common endocrine disorders in women of reproductive
age and has a strong genetic component. It is character-
ized by ovarian dysfunction and its clinical manifesta-
tions may include obesity, increased insulin resistance
and compensatory hyperinsulinemia, oligo-/anovulation
and infertility [35]. Studies regarding vitamin D status in
patients with PCOS show an inverse correlation between
vitamin D levels and metabolic risk factors, e.g. insulin
resistance, BMI, waist-to-hip-ratio, triglycerides, total
testosterone and DHEAS and a positive correlation with
insulin sensitivity [36-38]. Data on the role of gene var-
iants involved in vitamin D metabolism in PCOS are
sparse but suggest an association of VDR and vitamin D
level-related variants with metabolic and endocrine
parameters in women with PCOS [39]. Several studies
although limited by modest sample sizes have suggested
associations between VDR polymorphisms and the
development of PCOS as well as insulin resistance
[39-43]. Different distributions e.g. of VDR Apa-I and
Fok-I gene polymorphisms were found in a cohort of
162 women with PCOS and their controls [42]. It seems
possible that variants in the VDR through their effect on
luteinizing hormone, sex hormone binding globulin
levels and testosterone are involved in the pathogenesis
of PCOS [39,40]. Further genes involved in vitamin D
synthesis, hydroxylation and transport and their role in
PCOS are currently under investigation [39].
Clinical trials with either vitamin D supplementation
or administration of vitamin D3 analogues showed posi-
tive effects on insulin secretion, lipid profile, menstrual
cycle and follicular development and a decrease of fast-
ing and stimulated glucose and C-peptide levels [44-48].
However, most of the studies had rather small sample
sizes and experimental set-up was quite heterogenous.
One of the great confounders in all studies was the pre-
sence of obesity. In some studies an association of vita-
min D and insulin resistance was only seen in obese
patients or 25(OH)D3 levels were only associated with
 
Figure 3 Proposed health implications of vitamin D deficiency from infancy to seniority.
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obesity and insulin resistance but not with PCOS per se
[36,49,50]. Lower serum levels of 25(OH)D3 were shown
in obese PCOS patients (e.g. 31.9 ± 9.4 nmol/l) than in
non-obese (73.1 ± 20.2 nmol/l) [36,51]. Consequently,
the association of hypovitaminosis D with features of
PCOS may be associated with obesity but not with the
presence of PCOS. Recently it was hypothesized that
vitamin D deficiency is not only in association with obe-
sity but a potentially reason [52]. As vitamin D supple-
mentation evidently has positive effects on the outcome
of PCOS the question whether to substitute patients
with PCOS to ameliorate insulin resistance and prevent
other health complications, such as diabetes mellitus
type 2, has to be addressed in large intervention trials.
Vitamin D and endometriosis
An impairment of immunologic mechanism and inflam-
matory responses has been suggested to be involved in
the pathogenesis of endometriosis. Cyclic and early
pregnant endometrium is an extrarenal site of vitamin D
synthesis and action [21]. In endometriosis patients the
gene encoding for 1a-hydroxylase shows an enhanced
expression in ectopic endometrium [21]. Recent data
also indicate that women suffering from endometriosis
express more VDRs in their endometrial tissue [53] and
have higher serum levels of 25(OH)D3 than those of the
control group [54,55]. An analysis of VDR gene poly-
morphisms (ApaI, TaqI, FokI, BmsI) including 132
women with endometriosis and 133 controls found rela-
tively similar VDR polymorphism genotype frequencies
in cases and controls [56]. A small observational study
in 26 women with and 17 women without endometriosis
detected insignificantly higher serum and lower perito-
neal DBP concentrations [57]. However, Faserl and col-
leagues found about 3 times higher DBP levels
associated with the GC*2 allele product that was in
greater concentration in serum pools, as well as in single
validation samples in 56 women with endometriosis
compared to healthy controls. This finding may be
explained by an influence of vitamin D on local activity
of immune cells and cytokines maintaining endometrio-
sis and an insufficiency to activate macrophage’s phago-
cytotic function in those carrying the GC*2
polymorphism [58,59].
Vitamin D and hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy and especially pree-
clampsia (PE) are the most studied reproductive health
outcomes in association with maternal vitamin D status.
The syndrome PE is defined as the occurrence of hyper-
tension and proteinuria after 20 weeks of gestation, and
with a prevalence of 3-5% of all pregnancies worldwide
it is the leading cause of maternal and fetal morbidity
and mortality [60]. Seasonal patterns in PE suggest a
role for vitamin D and sunlight, because of a higher
incidence in winter and a lower incidence in summer
[61,62]. Compared with normal pregnancies, PE is char-
acterized by marked changes in vitamin D and calcium
metabolism [63] and already in the early 1990’s a role
for vitamin D in the pathogenesis of PE was hypothe-
sized [64]. Women with PE are known to have lower
circulating 25(OH)D3 levels than normotensive pregnant
women [65-68].
In nested case-control studies vitamin D deficiency in
pregnancy < 50 nmol/l of 25(OH)D3 was associated with
an almost 4-fold odds of severe PE [69] and vitamin D
deficiency < 37.5 nmol/l was even associated with a 5-
fold risk of developing PE [65]. Bodnar et al. showed
that 25(OH)D3 deficiency before 22 weeks of gestation
is an independent risk factor for the manifestation of PE
[65]. Interestingly, Robinson and colleagues recently
reported lower maternal 25(OH)D3 concentrations in 56
women with early onset PE and small for gestational age
(SGA) infants vs. infants with normal fetal growth sug-
gesting an impact of vitamin D on fetal growth through
placental mechanisms [70]. In a case-control study in 78
women near term with at least two blood pressure read-
ings above 140/90 mmHg and 109 controls, women
with low circulating 25(OH)D3 concentrations were
more likely to have hypertension [71]. In an earlier
study hypertensive pregnant women were not different
from the normotensive ones regarding plasma corrected
calcium and phosphate and urinary excretion of calcium
and phosphate, but had lower total and free calcitriol
index (ratio of total calcitriol on DBP) [72].
Not all of the data regarding vitamin D status and PE
prevalence are consistent and studies reporting no rela-
tionship have significantly lower case numbers [73-75].
While studies in the second and third trimester of
pregnancy suggest and association of hypovitaminosis D
and PE risk a nested-case control study conducted by
Powe et al. in first trimester found that total and free 25
(OH)D3 levels were not independently associated with
subsequent PE [75] and a recent prospective cohort
study of 221 Canadian women with high risk of PE
found no difference in the rates of PE, gestational hyper-
tension, preterm birth or composite adverse pregnancy
outcomes by 25(OH)D3 concentration [74]. The cited
studies on vitamin D and PE are not only conducted in
different populations but also differ considerably in their
experimental set-up, definition of vitamin D deficiency,
inclusion criteria and possible confounders so that the
discrepancy in study results can not easily be explained
and large-scale clinical trials are awaited to clarify this
issue. However, vitamin D supplementation studies to
prevent PE showed protective effects of vitamin D. The
first known study in this context was a controlled trial
in London in the 1940’s -1950’s with 5644 women in
which a reduction of 31.5% in PE was seen in women
who received a dietary supplement containing vitamins
Grundmann and von Versen-Höynck Reproductive Biology and Endocrinology 2011, 9:146
http://www.rbej.com/content/9/1/146
Page 5 of 12
(2,500 IU vitamin D), minerals and fish oil in compari-
son to the control group who did not receive any sup-
plement [76]. A recent study by Haugen et al. in a
cohort of 23,423 nulliparous women in Norway showed
a 27% reduction in the risk of PE in women who took
400-600 IU vitamin D supplements per day compared
to women without supplementation [77]. One small
RCT conducted in India, however finds no association
of vitamin D supplementation (1,200 IU vitamin D/day
and 375 mg calcium/day) with a reduced risk for PE but
a reduction in diastolic blood pressure of 8 mmHg [78].
In a unique investigation in a Finish birth cohort, Hyp-
ponen et al. observed that vitamin D supplementation
early in the first year of life is associated with a 50%
reduction of PE prevalence in the first pregnancy later
in life [79]. This suggests that vitamin D intake in
infancy may be involved in programming processes of
the immune system.
It remains unclear how vitamin D insufficiency or
deficiency might be involved in pathophysiologic pro-
cesses that cause PE but it may be linked with PE
through actions outside of its traditional calcium regula-
tory role. One mechanism suggested is the regulation of
maternal and placental immunological and inflammatory
responses, as it has been shown in experimental models
[80,81]. The placenta itself expresses 1a-hydroxylase
and thus produces the active metabolite 1a,25(OH)2D3
[82]. Whether this placental production of vitamin D is
a major contributor to the maternal vitamin D status or
has mainly paracrine functions is controversial [83,84].
In syncytiotrophoblasts from preeclamptic pregnancies
the expression and activity of 1a-hydroxylase are
restricted suggesting an important role for vitamin D at
the placental site of the disease [85]. There is evidence
that vitamin D regulates key target genes associated
with implantation, trophoblast invasion and implanta-
tion tolerance [86]. Regarding implantation tolerance,
Th2 cell induction is one of the critical steps required
for the maintenance of normal pregnancy whereas
impaired implantation and adverse reaction of maternal
metabolism to the fetus in PE is mediated by Th1-cyto-
kines [87]. This fetal placental interface may be influ-
enced by vitamin D, which has an important role in
promoting the shift to a Th2-dominated immune
response pattern [88]. The maternal response to reduced
placental perfusion in PE may equally be affected by
vitamin D. Maternal vitamin D deficiency may lead to
the increased inflammatory response that characterizes
PE as well as to endothelial dysfunction through direct
effects on angiogenesis gene transcription, including vas-
cular endothelial growth factor (VEGF) [89,90].
Vitamin D and gestational diabetes mellitus
Gestational diabetes (GDM) is becoming increasingly
more common and has long-term implications for the
health of mothers and their children. The former have
an increased risk of developing type 2 diabetes, while
their offspring have an increased risk of obesity and dia-
betes later in life [91]. Polymorphisms of vitamin D have
been associated with metabolic mechanisms, e.g. insulin
release and the maintenance of glucose tolerance [92]. A
genetic contribution of CYP27B1 polymorphisms may
modulate 25(OH)D3 levels in GDM patients as reported
by Ramos-Lopez et al. [93]. GDM in relation to mater-
nal vitamin D status is examined only in observational
studies [94-100]. In a nested case-control study 25(OH)
D3 levels < 50 nmol/l at 16 weeks gestation before the
onset of GDM was associated with a 2.7-fold increased
risk for the development of GDM later in pregnancy
independent of measured confounders [96]. At the time
of oral glucose tolerance testing at mid gestation two
reports noted significantly positive correlations between
25(OH)D3 concentrations and insulin sensitivity [94,98]
or fasting/2-hour blood glucose levels and HbA(1c)
[100] whereas no association was observed in another
large study in South India [99]. In another recent study
the prevalence of severe vitamin D deficiency (25(OH)
D3 < 37.5 nmol/l) in the second trimester of pregnancy
was higher in GDM compared to normoglycemic preg-
nant women [95].
Interestingly, after 1,25(OH)2D3 supplementation a
decrease in glucose and insulin levels was noted [101].
Lau and colleagues contribute to this evidence by
demonstrating that, in women with GDM a lower
serum 25(OH)D3 concentration was independently asso-
ciated with poorer glycemic control [100]. RCTs of vita-
min D supplementation, initiated early in pregnancy, are
now required to demonstrate whether vitamin D supple-
mentation might reduce the incidence or severity of
GDM.
Vitamin D and mode of delivery
Data from Merewood et al. show an inverse association
with having a primary cesarean section and vitamin D
status in 253 women. Severely vitamin D deficient
women with levels of 25(OH)D3 < 37.5 nmol/l delivered
nearly four times as often by cesarean section than
those with 37.5 nmol/l or greater (OR 3.84) [102]. No
association was found between obstructed labor ensuing
cesarean section and vitamin D status in a case-control
study (37 cases, 80 controls) of nulliparous women at
term in Pakistan [103]. These are the only studies so far
examining vitamin D status in pregnancy and mode of
delivery and therefore the issue needs further
investigation.
Vitamin D and spontaneous preterm birth
Spontaneous preterm birth (SPB) occurs before 37
weeks gestation. From a pathophysiological point of
view there are numerous reasons for SPB including
intrauterine infection and inflammation. One major
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factor is the presence of bacterial vaginosis, a disruption
of the normal balance of vaginal flora with increased
growth of anaerobic bacteria responsible for the release
of inflammatory cytokines, prostaglandins, and phospho-
lipase A2 [104-106]. A recent study by Bodnar et al.
showed a linear inverse dose-response association
between maternal vitamin D status and the prevalence
of bacterial vaginosis in early pregnancy [107]. Using a
large, representative data set with inclusion of 3,523
women Hensel et al confirmed the association of 25
(OH)D3 deficiency (< 75 nmol/l) and bacterial vaginosis
among pregnant women [108]. In a cross-sectional
study of African American adolescents bacterial vagino-
sis was shown to also be associated with vitamin D
insufficiency (25(OH)D3 < 50 nmol/l) [109].
Since vitamin D has immunmodulatory and anti-
inflammatory effects, such as the regulation of produc-
tion and function of cytokines and neutrophil degranu-
lation products that is important and relevant to
prevent microbial invasion one may expect a protective
effect on SPB risk [110-112]. The various cells of the
immune system express VDRs and are modulated by
vitamin D [113]. Although vitamin D action dampens
the activation of the acquired immune system in
response to autoimmunity, this hormone has key actions
that enhance the innate immune system. It is involved
in cell-mediated immunity by reducing the production
of inflammatory cytokines such as IL-1, 6 and TNF a
that are involved in SPB [89,110,114,115]. Human decid-
ual cells are able to synthesize active 1,25(OH)2D3.
Therefore several studies point to the fact that vitamin
D is involved in the regulation of acquired and innate
immune responses at the fetal-maternal interface across
gestation [89,110,116]. Vitamin D might reduce the risk
of SPB also by helping to maintain myometrial quies-
cence. Myometrial contractility is dependent on calcium
release within the muscle cell and this process is regu-
lated by vitamin D [117,118]. Although experimental
data are promising there is limited observational data
available on the relationship of vitamin D and SPB. A
recent prospective cohort study in 221 Canadian women
could not show an association of 25(OH)D3 deficiency
(< 50 nmol/l) or insufficiency (< 75 nmol/l) with pre-
term birth [74] whereas in another observational study
with 14 cases maternal 25(OH)D3 levels of < 28 nmol/l
at 28 to 32 weeks of gestation were associated with a
0.7 weeks shorter gestation in an all Caucasian sample
but not at 11 weeks gestation [119]. In another first tri-
mester cohort of 4,225 women with 40 cases of SPB ≤34
6/7 weeks the prevalence of vitamin D deficiency (25
(OH)D3 < 50 nmol/l) was comparable among women
who subsequently delivered preterm compared with
controls [120]. 25(OH)D3 levels < 80 nmol/l in HIV-
positive pregnant Tanzanian women were not associated
with an increased risk for preterm delivery [121]. In a
cohort of 82,213 singleton live births Bodnar et al.
found indirect evidence that vitamin D and seasonal
sunlight exposure are relevant for preterm birth. The
prevalence of SPB was lowest among women who con-
ceived in summer and fall and was highest among win-
ter and spring conceptions [61,122]. The strongest
evidence that vitamin D sufficiency may protect against
preterm birth may be reported in the near future by
Hollis and colleagues from a randomized controlled trial
of 600 white, black, and Hispanic mothers and supple-
mentation of 400 IU, 2,000 IU, or 4,000 IU/d of vitamin
D3 in early pregnancy [123]. More large studies are
awaited to validate these important findings that might
represent vitamin D supplementation as a simple and
inexpensive method to reduce the risk of this adverse
pregnancy outcome.
Vitamin D and other reproductive outcomes
Vitamin D seems to have a complex relation with fetal
growth that may vary by genotype, race and other vari-
ables that could not be identified yet. This relation
between maternal vitamin D status and fetal birth
weight has been studied in RCT’s [124-127] and a num-
ber of observational studies [15,99,119,128-135] with
mixed results. Due to confounding factors (e.g. maternal
nutritional status, calcium and phosphorus intake,
maternal prepregnant BMI, socioeconomic status), that
were not always considered in these analyses the out-
comes are hard to compare.
Despite the recognized role of vitamin D in bone meta-
bolism and prevention of osteoporosis in postmenopausal
women, the information available on the impact of vita-
min D status on maternal and fetal bone health is limited.
No systemic studies have examined the effect of vitamin
D status in the neonate on skeletal mineral content in
humans, particularly studies regarding isolated vitamin D
effects clearly separated from calcium effects are very
rare. Only a handful of observational studies
[119,128,131,136-139] and one RCT [124] reported con-
tradictory results. Therefore the importance of maternal
vitamin D status to fetal skeletal development is not suffi-
ciently investigated. Nevertheless we would like to point
the interested reader to well-written reviews of the
above-mentioned topics [16,140,141].
Breast milk is an ideal nutrient for a newborn but is
not sufficient to maintain newborn vitamin D levels
within a normal range. Many nursing mothers or their
infants require vitamin D supplementation for optimal
health. Because of the existence of well-written reviews
analyzing the available literature on vitamin D and lacta-
tion we refer the reader to these articles [140,142-144].
Vitamin D and fetal programming
Vitamin D induces more than 3,000 genes, many of
which have a role in fetal development [145]. Therefore,
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vitamin D may be particular relevant to the “develop-
mental origins” or “fetal programming hypothesis” in
which environmental factors such as vitamin D influ-
ence the genomic programming of fetal and neonatal
developmental and subsequent disease risk in both
childhood and adult life [146]. Interestingly, in later life,
children of mothers with low vitamin D serum levels
during pregnancy suffer more often from chronic dis-
eases such as wheezing and asthma [147-149], schizo-
phrenia [150,151], multiple sclerosis [152], type 1
diabetes mellitus and insulin resistance [153-158] sug-
gesting intrauterine programming as possible mechan-
ism [17,143,159,160]. Mechanisms underlying this long-
term effect of the intrauterine environment are not
known yet but epigenetic mechanisms that lead to per-
sistent changes in structure and function in endocrine
systems are hypothesized.
Vitamin D supplementation and toxicity issues
Although summer sunlight is the most potent source of
vitamin D, fortified foods or specific supplements take
on an increasing importance, especially in the winter at
northern latitudes (40°N). Dietary recommendations are
available in many European countries, the US and also
globally [161,162]. The updated dietary reference intakes
for calcium and vitamin D of the IOM published for the
US and Canada (e.g. IOM 600 IU for pregnant/lactating
women) are based primarily on the intake of vitamin D
to ensure skeletal health (Figure 2). Levels of 25(OH)D3
of 75-110 nmol/l provided optimal benefits for these
outcomes and can be obtained with daily doses of
1,800-4,000 IU [163,164]. Concerning optimal concen-
trations of 25(OH)D3 the IOM link serum 25(OH)D3
levels ≥50 nmol/l with the Recommended Dietary
Allowance that meets 97,5% of the US population’s
needs and a level of < 30 nmol/l with increased risk for
vitamin D-deficient rickets [162]. Supraphysiologic,
potentially toxic levels are defined as a 25(OH)D3 con-
centration above 150 nmol/l [5].
The optimal serum levels and intake for pregnancy are
not known [160,165]. While low doses of 400, 800 and
1,600 IU did little to improve vitamin D nutritional sta-
tus in pregnant women [126] in a very recent rando-
mized controlled trial vitamin D supplementation of
4,000 IU/d started at 12-16 weeks of gestation was safe
and most effective achieving sufficient levels in women
and their neonates regardless of race [166]. As with
other micronutrients, both low and excessively high
intakes of vitamin D are associated with increased risk
of adverse effects and long term outcomes of clinical
trials will provide more information on the safety of
relatively high levels of 25(OH)D3.
Conclusions
Vitamin D deficiency is still considered a problem of the
past by health care professionals and the public. Popula-
tions at risk include infants, children, pregnant and
postmenopausal women. We have reviewed the existing
evidence for a range of possible adverse health outcomes
during a women’s reproductive period that may relate to
low vitamin D status. Besides the classical diseases such
as rickets, osteoporosis and osteomalacia, vitamin D
deficiency in women might be associated with lower fer-
tility and an increased risk for adverse pregnancy out-
comes. Most of the findings in humans are associations
or based on animal and laboratory studies and can
therefore not determine causality. Available scientific
data are limited and well-conducted clinical trials are
still lacking. Contradictory results can be explained not
only by methodological differences. Genetic, ethnic and
racial differences as well as latitude of residence and
season may account to the observed discrepancies in
several reproductive health outcomes. Vitamin D defi-
ciency is often clinically unrecognized, however labora-
tory measurements are easy to perform, and treatment
of vitamin D deficiency is inexpensive. Oral supplemen-
tation is the best-tolerated and the most effective route
of administration. At this point optimal levels of 25(OH)
D3 for the non-classical actions of vitamin D in the
reproductive period are not clear. Pressing questions
awaiting an answer include the optimal level of vitamin
D in women during their reproductive period and espe-
cially in pregnancy to achieve maximal benefit for
mother and fetus and whether vitamin D supplementa-
tion started preconceptionally is protective against pree-
clampsia and other adverse pregnancy outcomes. High
quality, large-scale RCTs are required to determine the
optimal 25(OH)D3 levels in the reproductive period and
the amount of vitamin D supplementation required to
achieve those levels for the numerous actions of vitamin
D throughout a woman’s life. Confirmation of experi-
mental observations relating to the risk of vitamin D
deficiency would have important public health
implications.
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